Abstract:ObjectiveTo preliminary study clinical efficacy and toxicity of endostatin (ES) combined radiotherapy and chemotherapy in advanced nonsmall cell lung cancer (NSCLC), and evaluate its effectiveness and safety. MethodsWe retrospectively reviewed 64 patients with ⅢBⅣ stage NSCLC of Harbin Medical University Cancer Hospital from February 2009 to February 2012.The patients were divided into two groups:chemoradiotherapy group, 39 patients and ES add chemoradiotherapy group, 25 patients. The shortterm effect, the total efficiency, median survival time, progressionfree survival time and diseasefree survival time were compared. ResultsThe total effective rate of chemoradiotherapy group was 76.9%, while the total effective rate of ES add chemotherapy group was 84.0%（χ2=0.47, P=0.492）. Chemoradiotherapy group, compared to ES add chemotherapy group, the median survival time, median progressionfree survival time, median diseasefree survival time were 11.52 months vs 16.51 months (χ2=3.74, P=0.042), 7.32 months vs 10.37 months (χ2=5.32, P=0.025) and 5.21 months vs 7.57 months (χ2=4.56, P=0.035)respectively. The mainly adverse drug reactions were hematologic toxicity and gastrointestinal reactions, but there were no significant differences between the two groups; radiotherapy side effects mainly showed the grade 1 to 2 radiationinduced lung injury and radiation esophagitis (chemotherapy group had one case of grade 3 radiationinduced lung injury), but also had no significant differences between the two groups. ConclusionES combined chemoradiotherapy can achieve a better shortterm clinical efficacy without increasing adverse effects of radiotherapy or chemotherapy in advanced nonsmall cell lung cancer.

Key words:Carcinoma, non-small cell lung,Radiotherapy,Chemotherapy, adjuvant,Endostatins